ACE program
Introducing the Predictive Oncology ACE program
Welcome to the ACE (Accelerating Compound Exploration) program, an initiative we are launching at Predictive Oncology to help academic and research institutions to advance their drug discovery. Our company created ACE to grant early-stage academic drug development groups and technology transfer offices access to the company’s PEDAL platform. PEDAL pairs active machine learning with an extensive biobank of 150K privately held tumor samples and in vitro assay results to help evaluate drug compounds and enable more informed selection of drug-tumor type combinations
Be a part of PEDAL
Compounds selected for the ACE program will be included in PEDAL campaigns with shared non-exclusive rights to the resultant tumor response data. Participation will be provided at no up-front cost to the investigator or institution.
Applications are being accepted here through March 31 for the first phase of the ACE program.
Additional information about Predictive Oncology’s technology and the submission process can be found here.

News & resources
“Pamela’s unwavering passion for a cancer cure paved the way for an incredible opportunity to directly make a difference in the lives of countless people,”...
“The way in which Predictive Oncology utilizes the power of predictive models offers the potential to optimize the utilization of resources, improve patient outcomes, and...
Life Sciences Knowledge Hub, recognized as the fastest-growing life sciences media platform, met with our Chief Executive Officer, Raymond F. Vennare, and Chief Business...